Immunogenicity of a trivalent influenza virus vaccine comprised of recombinant haemagglutinin proteins (FluBlOk) in the elderly

Trial Profile

Immunogenicity of a trivalent influenza virus vaccine comprised of recombinant haemagglutinin proteins (FluBlOk) in the elderly

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Nov 2010

At a glance

  • Drugs Influenza virus RIV3 vaccine-(FluBlok) (Primary) ; Influenza virus vaccine
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors Protein Sciences Corporation
  • Most Recent Events

    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top